Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

References

• International Agency for Research on Cancer. Cervical cancer. Estimated incidence, mortality and prevalence worldwide in 2012, 2014 [cited 2014 Nov 16]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191:114–120.
   PubMed Web of Science ®Google Scholar
• Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin. 2006;22:663–670.
   PubMed Web of Science ®Google Scholar
• Annemans L, Remy V, Lamure E, et al. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ. 2008;11:135–150.
   PubMedGoogle Scholar
• Low JJ, Ko Y, Ilancheran A, et al. Health and economic burden of HPV-related diseases in Singapore. Asian Pac J Cancer Prev. 2012;13:305–308.
   PubMedGoogle Scholar
• Salo H, Leino T, Kilpi T, et al. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int J Cancer. 2013;133:1459–1469.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19.
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. Part B: biological agents. Lancet Oncol. 2009;10:321–322.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–1056.
   PubMed Web of Science ®Google Scholar
• Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182–192.
   PubMed Web of Science ®Google Scholar
• Moscicki AB. HPV infections in adolescents. Dis Markers. 2007;23:229–234.
   PubMed Web of Science ®Google Scholar
• Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002;109:96–98.
   PubMed Web of Science ®Google Scholar
• Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010;70:8569–8577.
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004;190:2077–2087.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev. 2010;19:1585–1594.
   PubMed Web of Science ®Google Scholar
• Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123–137.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235–240.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–1765.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255.
   PubMed Web of Science ®Google Scholar
• Romanowski B, De Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975–1985.
   PubMed Web of Science ®Google Scholar
• De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010;28:6247–6255.
   PubMed Web of Science ®Google Scholar
• Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8:390–397.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10:2147–2162.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–314.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–110.
   PubMed Web of Science ®Google Scholar
• Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012;131:106–116.
   PubMed Web of Science ®Google Scholar
• Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208:1391–1396.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743–753.
   PubMed Web of Science ®Google Scholar
• Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1:408–419.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32:5087–5097.
   PubMed Web of Science ®Google Scholar
• Lang Kuhs KA, Porras C, Schiller JT, et al. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol. 2014;180:599–607.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Nat Cancer Inst. 2011;103:1444–1451.
   PubMed Web of Science ®Google Scholar
• Lang Kuhs KA, Gonzalez P, Rodriguez AC, et al. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica vaccine trial. J Infect Dis. 2014;210:1890–1899.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial. Lancet Oncol. 2011;12:862–870.
   PubMed Web of Science ®Google Scholar
• Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PloS One. 2013;8:e68329.
   PubMed Web of Science ®Google Scholar
• Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer. 2010;20:404–410.
   PubMed Web of Science ®Google Scholar
• Konno R, Tamura S, Dobbelaere K, et al. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer. 2010;20:847–855.
   PubMed Web of Science ®Google Scholar
• Konno R, Yoshikawa H, Okutani M, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: open follow-up of a randomized clinical trial up to 4 years post-vaccination. Hum Vaccin Immunother. 2014;10:1781–1794.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Chen W, Ym H, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135:2612–2622.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213–2227.
   PubMed Web of Science ®Google Scholar
• Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22:361–373.
   PubMed Web of Science ®Google Scholar
• Struyf F, Colau B, Wheeler CM, et al. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Clin Vaccine Immunol. 2015;22:235–244.
   PubMed Web of Science ®Google Scholar
• Miltz A, Price H, Shahmanesh M, et al. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PloS One. 2014;9:e90348.
   PubMed Web of Science ®Google Scholar
• La Torre G, De Waure C, Chiaradia G, et al. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine. 2007;25:8352–8358.
   PubMed Web of Science ®Google Scholar
• Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–789.
   PubMed Web of Science ®Google Scholar
• Medeiros LR, Rosa DD, Da Rosa MI, et al. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. 2009;19:1166–1176.
   PubMed Web of Science ®Google Scholar
• Rodriguez AC, Solomon D, Herrero R, et al. Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol. 2013;178:752–760.
   PubMed Web of Science ®Google Scholar
• Kreimer A, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015 [cited 2015 Jun 9]. DOI:10.1016/S1470-2045(15)00047-9.
   Web of Science ®Google Scholar
• Van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44:32–38.
   Web of Science ®Google Scholar
• Van Alewijk D, Kleter B, Vent M, et al. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay. J Clin Microbiol. 2013;51:1171–1178.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Nat Cancer Inst. 2009;101:475–487.
   PubMedGoogle Scholar
• Pirog EC, Lloveras B, Molijn A, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014;27:1559–1567.
   PubMed Web of Science ®Google Scholar
• Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14:2191–2199.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337:76–84.
   PubMed Web of Science ®Google Scholar
• Castanon A, Landy R, Brocklehurst P, et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. BMJ. 2014;349:g6223.
   PubMedGoogle Scholar
• Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.
   PubMed Web of Science ®Google Scholar
• Boxus M, Lockman L, Fochesato M, et al. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine. 2014;32:3232–3236.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother. 2014;10:1155–1165.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6:1242–1250.
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–1802.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization, vaccines and biologicals. Summary of the SAGE April 2014 meeting. [cited 2014 Nov 16]. Available from: http://www.who.int/immunization/sage/meetings/2014/april/report_summary_april_2014/en/
   Google Scholar
• Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343:d5775.
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
   PubMed Web of Science ®Google Scholar
• Vaccines and Related Biological Products Advisory Committee (VRBPAC). Cervarix. Human papillomavirus Bivalent (types 16 and 18) vaccine, recombinant. Briefing document, 2009 Sep 9. [cited 2015 Sep 15]. Available from: http://www.fda.gov/downloads/Adviso…uctsAdvisoryCommittee/UCM181371.pdf
   Google Scholar
• Di Mario S, Basevi V, Lopalco PL, et al. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res. 2015;435141. DOI:10.1155/2015/435141.
   Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89:465–492.
   PubMedGoogle Scholar
• Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015 [cited 2015 May 31]. DOI:10.1586/14760584.2015.1051470.
   PubMed Web of Science ®Google Scholar
• Bosch FX, De Sanjosé S, Castellsagué X. The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov. 2011;1:377–380.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Clinical Study Register. Study ID: 580299/007. 2014 [cited 2015 Jun 20]. Available from: www.gsk-clinicalstudyregister.com/study/580299/007#rs
   Google Scholar
• GlaxoSmithKline. Clinical Study Register. Study ID: 109616 (Y7). 2014 [cited 2015 Jun 20]. Available from: http://www.gsk-clinicalstudyregister.com/study/109616%20(Y7)#rs
   Google Scholar
• Moscicki AB, Harper DM, Naud P, et al. HPV-16/18 AS04-adjuvanted vaccine: sustained immunogenicity against HPV-31 and HPV-45 non-vaccine oncogenic types up to 9.4 years. Presented at the 30th International Papillomavirus Conference and Public Health Workshops (HPV 2015); 2015 Sep 17–21; Lisbon, Portugal.
   Google Scholar
• Lowy DR, Herrero R, Hildesheim A. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 2015;16:e226–e233.
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Safaeian M, Hildesheim A, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(R). Vaccine. 2012;31:165–170.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Wheeler CM, Romanowski B, et al. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012;31:234–241.
   PubMed Web of Science ®Google Scholar
• Van Kriekinge G, Castellsague X, Cibula D, et al. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014;32:733–739.
   PubMed Web of Science ®Google Scholar
• Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32:26–32.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110:2804–2811.
   PubMed Web of Science ®Google Scholar
• Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111:1824–1830.
   PubMed Web of Science ®Google Scholar
• Public Health England. Declines in genital warts since start of the HPV immunisation programme. Health Protect Rep – Wkly Rep. 2014 [cited 2015 Sep 15];9(22). Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/441554/hpr2215.pdf
   Google Scholar
• Turner HC, Baussano I, Garnett GP. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PloS One. 2013;8:e75552.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions. 2014 [cited 2014 Nov 16]. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf
   Google Scholar
• Brotherton JM. Could one dose of bivalent HPV vaccine prevent cervical cancer? Lancet Oncol. 2015 [cited 2015 Jun 10]. DOI:10.1016/S1470-2045(15)00046-7.
   Web of Science ®Google Scholar
• Gonzalez P, Hildesheim A, Herrero R, et al. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine. 2015;33:2141–2151.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Levin C, Mosqueira-Lovon NR, et al. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Rev Panam Salud Publica. 2012;32:426–434.
   PubMed Web of Science ®Google Scholar
• Burger EA, Sy S, Nygard M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PloS One. 2014;9:e89974.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Apter D, Baussano I, et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015;33:1284–1290.
   PubMed Web of Science ®Google Scholar